Reforgene named a 2023 Future Healthcare Top 100 company

The 2023 Seventh Future Healthcare Top 100 conference, themed "Crossing East and West", interpreted the pioneering spirit of healthcare innovation trailblazers. The conference officially opened on May 5 and released the 2023 Future Healthcare Top 100 list on the evening of May 6. Reforgene was selected into the China Innovative Biopharmaceutical TOP100. The selection indicates that Reforgene has been recognized by industry experts, industry observers and analysis institutions in the fields of gene editing technology and drug innovation. Reforgene will continue to be driven by technological innovation and promote its growth into a globally competitive biotechnology enterprise.

About the 2023 Future Healthcare Top 100

Founded in 2015 by VB100, VBDATA and Danke Research Institute, the Future Healthcare Top 100 list is the first domestic list for innovative healthcare companies targeting non-listed enterprises. It aims to select Chinese innovative healthcare providers that truly represent the future of healthcare, discover the core strength of China's future healthcare industry, and promote the innovation and transformation of the health industry. Over seven years, the Future Healthcare Top 100 selection system has been continuously enriched, gradually building a global innovative healthcare selection ecosystem for enterprises, investment institutions and industrial parks, and extending to innovative product and innovative technology selections.

This selection is open to non-listed enterprises in the healthcare field. Based on the VB100 value evaluation model, through the process of enterprise self-application, VB100 review committee evaluation, cross-review by supporting institutions and final review by the expert committee, it selects the TOP100 innovative enterprises by valuation from five major fields (medical devices/biomedicine/digital healthcare/medical services/business and supply chain services). Beyond valuation, it also examines the growth and annual performance of candidate enterprises across four first-level indicators, namely human resources, knowledge resources, key partner resources and market performance, totaling 17 second-level indicators.